The cicada COVID variant, officially designated as BA.3.2, is emerging as a significant concern in the United States due to its potential to evade immunity from vaccines and prior infections. As of March 2026, BA.3.2 has been detected in at least 25 states, raising alarms among health officials and the public alike.

First identified in South Africa in November 2024, BA.3.2 has rapidly spread, with reports indicating its presence in at least 23 countries. The variant is characterized by a staggering 70 to 75 mutations in its spike protein, which may allow it to circumvent the immune responses generated by existing vaccines. Andrew Pekosz, Ph.D., noted, “It has a lot of mutations that may cause it to look different to your immune system,” underscoring the variant’s potential threat.

Despite the alarming number of mutations, experts are cautious about the variant’s implications for disease severity. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This observation provides a glimmer of hope amidst growing concerns, suggesting that while BA.3.2 may spread more easily, it does not necessarily lead to worse outcomes.

Current data shows that during the week ending March 21, 2026, BA.3.2 was detected in approximately 11% of wastewater samples in the U.S., indicating its increasing prevalence. The variant was first reported in the U.S. in June 2025, and since then, it has continued to spread, prompting the World Health Organization (WHO) to classify it as a “variant under monitoring” in December 2025.

Common symptoms associated with BA.3.2 include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms are consistent with those of previous COVID-19 variants, making it crucial for individuals to remain vigilant and seek testing if they experience any of these signs.

While the existing vaccines have shown effectiveness against severe illness from COVID-19, their efficacy against BA.3.2 remains a topic of investigation. Dr. Amesh A. Adalja remarked, “The existing vaccine is likely to protect against what matters most: serious illness,” providing some reassurance. However, the exact impact of BA.3.2 on disease severity is still unclear, and it is uncertain how effective current vaccines will be against this variant.

Details remain unconfirmed regarding the reasons for BA.3.2’s resurfacing and its implications for public health moving forward. As health authorities continue to monitor the situation, further developments are expected, and the public is encouraged to stay informed about the latest guidance from health officials.

The post Cicada COVID Variant BA.3.2 Raises Concerns in the United States appeared first on News Casino.

The BA.3.2 variant, nicknamed Cicada, is spreading quickly across the United States. As of February 2026, it has been detected in 23 countries and 29 U.S. states, raising alarms among health officials.

First identified in November 2024 in Africa, the BA.3.2 variant carries 70 to 75 genetic changes in its spike protein, which may affect how the virus interacts with the immune system. Experts are concerned that these mutations could allow the variant to evade immunity from previous infections or current vaccines. “Due to the high number of mutations, experts worry the variant may more easily bypass immunity from previous infections or current vaccines,” a health official stated.

Despite these concerns, there is currently no evidence that BA.3.2 causes more severe disease than previous variants. Emily Ronay Johnston, a virologist, noted, “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26.” This sentiment is echoed by other experts who emphasize that the majority of people infected with this variant report relatively mild illness, particularly among those who are vaccinated.

COVID-19 continues to pose a public health challenge, with the virus causing 300-500 deaths per week in the U.S. The first U.S. case of BA.3.2 was detected in a traveler in June 2025, indicating that the variant has been present for several months. While the variant may infect people more widely due to immune evasion, it is not considered more dangerous than its predecessors.

The historical context of the BA.3.2 variant is important, as it is descended from the Omicron variant, which emerged in late 2021. This lineage has been characterized by its rapid spread and mutations, leading to ongoing adjustments in public health responses and vaccine strategies.

As health officials continue to monitor the situation, the long-term impact of the BA.3.2 variant on public health remains unclear. The effectiveness of current vaccines against this variant is also not fully confirmed. Details remain unconfirmed.

In summary, while the Cicada variant is spreading rapidly and presents challenges due to its mutations, experts advise that there is no immediate cause for panic. The situation is being closely monitored as more data becomes available, and public health measures continue to adapt to the evolving landscape of COVID-19 variants.

The post Covid 19 cicada variant: COVID-19 Cicada Variant Spreads Rapidly Across the U.S. appeared first on News Casino.